OKYO Pharma Limited (OKYO) Stock Ticker
Market factors today
Unlock the full OKYO picture
About OKYO Pharma Limited
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
OKYO stock facts
| Ticker symbol | OKYO |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $52.9M |
| CEO | Robert J. Dempsey |
| Employees | 5 |
| Headquarters | London, GL, GB |
| IPO date | 2022-05-17 |
| Website | www.okyopharma.com |
What you can see for OKYO on Tickr
Live OKYO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the OKYO report.
Rankings
FAQ
What is the ticker symbol for OKYO Pharma Limited?
The ticker symbol for OKYO Pharma Limited is OKYO, listed on the NASDAQ Capital Market.
What is OKYO?
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine…